ERBB2 and breast carcinoma: As expected, we could show that the synthesized and fluorescence-labeled anti-ErbB2-anti-ErbB3-bsFabs exhibited improved fluorescence intensities in mammalian breast cancer cell lines compared with the single Fabs alone.